Top

BMC Musculoskeletal Disorders

Published in:

Open Access 01-12-2016 | Research article

Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment

Authors: Rhys D. R. Evans, Christopher M. Laing, Coziana Ciurtin, Stephen B. Walsh

Published in: BMC Musculoskeletal Disorders | Issue 1/2016

Abstract

Background

Primary Sjögren syndrome (pSS) is a common autoimmune condition which primarily affects epithelial tissue, often including the kidney causing either tubulointerstitial nephritis (TIN) or more rarely, an immune complex related glomerulonephritis.

Methods

We describe the clinical, biochemical and histological characteristics of 12 patients with pSS related TIN and their response to treatment with antiproliferative agents. All 12 patients were investigated and treated at the UCL Centre for Nephrology in London.

Results

All patients had TIN demonstrated via needle biopsy; immunophenotyping showed that the interstitial infiltrate was predominantly a CD4+ T-cell infiltrate. Urinary acidification testing demonstrated distal renal tubular acidosis in 8 patients. Proximal tubular dysfunction was present in 5 patients. All but 1 patient were treated with antiproliferative agents and most also with a reducing course of steroids. In the treated patients, there was a significant improvement in the serum creatinine and measured GFR.

Conclusion

Patients with pSS TIN have significant renal impairment and other functional tubular defects. There is a mononuclear lymphocytic infiltrate on renal biopsy and this appears to be mainly a CD4+ T-cell infiltrate. Treatment with mycophenolate (and corticosteroids) improves the renal function in patients with pSS TIN.

Sjögren H. Zur Kenntnis Der Keratoconjunctivitis Sicca Ii. Acta Ophthalmol (Copenh). 1935;13(1–39).

Moutsopoulos HM. Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994;72:162–5.PubMedCrossRef

Aasarød K, Haga H-J, Berg KJ, Hammerstrøm J, Jørstad S. Renal involvement in primary Sjögren’s syndrome. QJM. 2000;93:297–304.PubMedCrossRef

Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32:265–74.PubMedCrossRef

Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG. Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis Rheum. 2013;65:2945–53.PubMedCrossRef

Talal N, Zisman E, Schur PH. Renal Tubular Acidosis, Glomerulonephritis and Immunologic Factors in Sjogren’s Syndrome. Arthritis Rheum. 1968;11:774–86.PubMedCrossRef

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.PubMedPubMedCentralCrossRef

Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. Kidney Int. 2007;71:1310–6.PubMedCrossRef

Wrong O, Davies HEF. The Excretion of Acid in Renal Disease. QJM. 1959;28:259–313.PubMed

10.

Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum. 2008;58:15–25.PubMedCrossRef

11.

Kang HI, Fei HM, Saito I, Sawada S, Chen SL, Yi D, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjögren’s syndrome. J Immunol. 1993;150:3615–23.PubMed

12.

Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, et al. Primary Sjögren Syndrome in Spain: Clinical and Immunologic Expression in 1010 Patients. Med (Baltimore). 2008;87:210–9.CrossRef

13.

Ramos-Casals M, Brito-Zerón P, Solans R, Camps M-T, Casanovas A, Sopeña B, et al Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology. 2014;53:321–31.

14.

Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M, Cavazzana I, et al. Clinical and morphological features of kidney involvement in primary Sjögren’s syndrome. Nephrol Dial Transplant. 2001;16:2328–36.

15.

Amarante GBD, Zotin MC, Rocha E, Delgado AG, Jr. ML, Gomes CP. Renal tubular dysfunction in patients with primary Sjögren syndrome. Clin Nephrol. 2014;81:185–91.CrossRef

16.

Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjögren’s syndrome: a study of 78 patients. Rheumatology. 1999;38:1113–20.PubMedCrossRef

17.

Ren H, Wang W-M, Chen X-N, Zhang W, Pan X-X, Wang X-L, et al. Renal involvement and followup of 130 patients with primary Sjögren’s syndrome. J Rheumatol. 2008;35:278–84.PubMed

18.

Eriksson P, Denneberg T, Larsson, L & Lindström F. Biochemical Markers of Renal Disease in Primary Sjögren’s Syndrome. (2010). at http://informahealthcare.com/doi/abs/10.3109/00365599509180018.

19.

Bogdanović R, Basta-Jovanović G, Putnik J, Stajić N & Paripović A. Renal involvement in primary Sjogren syndrome of childhood: case report and literature review. (2014). at http://informahealthcare.com/doi/abs/10.3109/s10165-012-0633-x.

20.

Takada K, Takiguchi M, Konno A, Inaba M. Spontaneous development of multiple glandular and extraglandular lesions in aged IQI/Jic mice: a model for primary Sjögren’s syndrome. Rheumatology. 2004;43:858–62.PubMedCrossRef

21.

Rosenberg M, Schendel P, Fa M, Jl P. Characterization of immune cells in kidneys from patients with Sjogren’s syndrome. Am J Kidney Dis Off J Natl Kidney Found. 1988;11:20–2.CrossRef

22.

Matsumura R, Kondo Y, Sugiyama T, M S, T K, K T, et al. Immunohistochemical identification of infiltrating mononuclear cells in tubulointerstitial nephritis associated with Sjogren’s syndrome. Clin Nephrol. 1988;30:335–40.

23.

Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and Local Interleukin-17 and Linked Cytokines Associated with Sjögren’s Syndrome Immunopathogenesis. Am J Pathol. 2009;175:1167–77.PubMedPubMedCentralCrossRef

24.

Lin X, Rui K, Deng J, Tian J, Wang X, Wang S, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann. Rheum. Dis. annrheumdis–2013–204584 (2014). doi:10.1136/annrheumdis-2013-204584.

25.

Kapsogeorgou EK, Christodoulou MI, Panagiotakos DB, Paikos S, Tassidou A, Tzioufas AG, et al. Minor Salivary Gland Inflammatory Lesions in Sjögren Syndrome: Do They Evolve? J Rheumatol. 2013;40:1566–71.PubMedCrossRef

26.

Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2012;8:399–411.PubMedCrossRef

27.

Preddie DC, Markowitz GS, Radhakrishnan J, Nickolas TL, D’Agati VD, Schwimmer JA, et al. Mycophenolate Mofetil for the Treatment of Interstitial Nephritis. Clin J Am Soc Nephrol. 2006;1:718–22.

28.

Morris R, Fudenberg H. Impaired renal acidification in patients with hypergammaglobulinaemia. Med Baltim. 1967;46:57–69.CrossRef

29.

Spruce BA, Baylis PH, Kerr DN, Morley AR. Idiopathic hypergammaglobulinaemia associated with nephrogenic diabetes insipidus and distal renal tubular acidosis. Postgrad Med J. 1984;60:493–4.PubMedPubMedCentralCrossRef

30.

Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, et al. Renal Involvement in Primary Sjögren’s Syndrome: A Clinicopathologic Study. Clin J Am Soc Nephrol. 2009;4:1423–31.PubMedPubMedCentralCrossRef

Title: Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment
Authors: Rhys D. R. Evans
Christopher M. Laing
Coziana Ciurtin
Stephen B. Walsh
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Musculoskeletal Disorders / Issue 1/2016
Electronic ISSN: 1471-2474
DOI: https://doi.org/10.1186/s12891-015-0858-x

2024 ASCO Annual Meeting

Springer Medicine

Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment

Abstract

Background

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis

Modic changes in the lumbar spine and their association with body composition, fat distribution and intervertebral disc height – a 3.0 T-MRI study

Does the addition of hip strengthening exercises improve outcomes following total knee arthroplasty? A study protocol for a randomized trial

Physical examination findings and their relationship with performance-based function in adults with knee osteoarthritis

Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies

The osteoblast as an inflammatory cell: production of cytokines in response to bacteria and components of bacterial biofilms